Healthy men help compare new allergy drug to standard treatment
NCT ID NCT07246252
First seen Nov 25, 2025 · Last updated May 16, 2026 · Updated 21 times
Summary
This study tested a new version of the allergy drug omalizumab (called CMAB007) against the approved drug Xolair. It involved 114 healthy Chinese men aged 18 to 45. The goal was to see how the body absorbs and processes each drug and to check for any side effects. This is an early-stage study to gather information, not to treat a disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS (HV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Xuhui Central Hospital, Shanghai
Shanghai, China
Conditions
Explore the condition pages connected to this study.